In addition, the proteasome inhibitor MG132 inhibits tumor development by inactivating NF-κB signaling, synergizes with paclitaxel (PTX) to enhance antitumor activity, induces apoptosis and G2 arrest, and inhibits viability and migration to inhibit tumor progression [21]. Here, NFKB1 is linked to neoplasm.